Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Recombinant PDL1 (Sugemalimab Biosimilar) antibody (Biotin)

The Biotin-conjugated Humanized Monoclonal anti-PDL1 (Sugemalimab Biosimilar) antibody (ABIN7829436) specifically detects PDL1 (Sugemalimab Biosimilar). The antibody is reactive with Human samples.
Catalog No. ABIN7829436
$189.05
Plus shipping costs $50.00
50 μg
Shipping to: United States
Delivery in 40 to 51 Business Days

Quick Overview for Recombinant PDL1 (Sugemalimab Biosimilar) antibody (Biotin) (ABIN7829436)

Target

PDL1 (Sugemalimab Biosimilar)

Antibody Type

Recombinant Antibody

Reactivity

Human

Host

  • 1
Humanized

Clonality

  • 1
Monoclonal

Conjugate

  • 1
This PDL1 (Sugemalimab Biosimilar) antibody is conjugated to Biotin

Grade

Research Grade
  • Purpose

    Biotinylated Anti-PD-L1(sugemalimab biosimilar) mAb

    Isotype

    IgG4
  • Comment

    Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.

    Restrictions

    For Research Use only
  • Format

    Lyophilized

    Reconstitution

    Please see Certificate of Analysis for specific instructions of reconstitution.

    Buffer

    Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose is added as protectants before lyophilization.

    Storage

    -20 °C,-80 °C

    Storage Comment

    Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.

    Expiry Date

    12 months
  • Target

    PDL1 (Sugemalimab Biosimilar)

    Alternative Name

    Sugemalimab Biosimilar

    Target Type

    Biosimilar

    Background

    Synonyms Target:B7-H,B7H1,PDL1,PD-L1,hPD-L1,PDCD1L1,PDCD1LG1
    Synonyms Antibody:Cejemly,CS-1001,CS1001,CS 1001,Sugelimab,WBP-3155,WBP3155,WBP 3155,Zegema,Zegemet,Zegemex,ZEJIEMEI

    UniProt

    Q9NZQ7
You are here:
Chat with us!